Stelara and Fiasp/NovoLog. They accounted for $50.5 billion in total Part D covered prescription drug costs from June 2022 to May 2023, CMS said. The talks are set to take place later this year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback